VVT Med Provides Update on Management Cease Trade Order
VVT Med’s Italian Breakthrough Overshadowed as Cease Trade Order Drags Shares to Multi‑Year Lows
The most recent release (2026‑05‑29) is a bi‑weekly status update on the Management Cease Trade Order (MCTO) imposed by the BCSC. It repeats that the Company expects to file its audited 2025 annual financials and the Q1 2026 interim report by June 29, 2026. Trading by the CEO and CFO remains prohibited, and the Company cannot issue securities to insiders except for pre‑existing commitments. No material changes from previous default disclosures are reported.
This update is entirely expected and contains no new information. The MCTO was first announced on April 17, 2026, and the timeline and restrictions have not changed. As a regular compliance update, it does not alter the fundamental picture. It is Routine – Negative because it confirms the company remains in a disclosure default, but the market already priced in the MCTO when it was announced as Material – Negative on May 1, 2026.
VVT Med Inc. is a commercial‑stage medical device company focused on the treatment of varicose veins. Its flagship ScleroSafe System is a non‑thermal, non‑tumescent (NT‑NT) catheter‑directed sclerotherapy platform that simultaneously injects sclerosant and aspirates blood. The system is FDA‑cleared and CE‑marked, allowing sales in the U.S. and European Economic Area. The company is building a global distribution network, with recent agreements for India (Medworks), Italy (Uber Ros), and an initial U.S. order from Northwell Health.